• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by OraSure Technologies Inc. (Amendment)

    1/26/22 3:01:42 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care
    Get the next $OSUR alert in real time by email
    SC 13G/A 1 doc1.htm Schedule 13G/A


     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G/A
     
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 01)*
     
    ORASURE TECHNOLOGIES INC 

    (Name of Issuer)
     
    Common Stock

    (Title of Class of Securities)
     
    68554V108

    (CUSIP Number)
     
    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
         ⌧ Rule 13d-1(b)
     
         □ Rule 13d-1(c)
     
         □ Rule 13d-1(d)
     
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     


     
     

     
     
    CUSIP No.  68554V108            
     
          
    1   NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
     MANAGED ACCOUNT ADVISORS LLC
    000000000
       
    2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)   □
      (b)   ⌧
       
    3 SEC USE ONLY
      
      
       
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
      
     Delaware
        
    NUMBER OF SHARES BENEFICIALLY  OWNED BY EACH REPORTING PERSON WITH:  5   SOLE VOTING POWER
      
     0
       
    6 SHARED VOTING POWER
      
     0
       
    7 SOLE DISPOSITIVE POWER
      
     4,255,738
       
    8 SHARED DISPOSITIVE POWER
      
     65,641
       
    9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
      
     4,321,379
       
    10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      
     □
       
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
      
     6.0 %
       
    12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      
     IA
     
    FOOTNOTES
      
     
     
     

     
     
    Item 1.

     
    (a)
    Name of Issuer
     
     
    ORASURE TECHNOLOGIES INC

     
    (b)
    Address of Issuer’s Principal Executive Offices
     
     
    150 WEBSTER ST
    BETHLEHEM, PA 18015

    Item 2.

     
    (a)
    Name of Person Filing
     
     
    MANAGED ACCOUNT ADVISORS LLC

     
    (b)
    Address of Principal Business Office or, if none, Residence
     
     
    101 HUDSON STREET
    9TH FLOOR
    JERSEY CITY, NJ 07302

     
    (c)
    Citizenship
     
     
    Delaware

     
    (d)
    Title of Class of Securities
     
     
    Common Stock

     
    (e)
    CUSIP Number
     
     
    68554V108

     
    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     
    (a)
    □
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     
    (b)
    □
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     
    (c)
    □
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     
    (d)
    □
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

     
    (e)
    ⌧
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     
    (f)
    □
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     
    (g)
    □
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     
    (h)
    □
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     
    (i)
    □
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     
    (j)
    □
    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).

     
    (k)
    □
    A group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     
     
     

     
     
    Item 4.
    Ownership.
     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     
    (a)
    Amount beneficially owned: 4,321,379

     
    (b)
    Percent of class: 6.0 %

     
    (c)
    Number of shares as to which the person has:

     
    (i)
    Sole power to vote or to direct the vote: 0

     
    (ii)
    Shared power to vote or to direct the vote: 0

     
    (iii)
    Sole power to dispose or to direct the disposition of: 4,255,738

     
    (iv)
    Shared power to dispose or to direct the disposition of: 65,641

    Item 5.
    Ownership of Five Percent or Less of a Class
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following □.
     
    Not Applicable
     
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.
     
    Not Applicable
     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
     
    Not Applicable
     
    Item 8.
    Identification and Classification of Members of the Group
     
    Not Applicable
     
    Item 9.
    Notice of Dissolution of Group
     
    Not Applicable
     
     
     

     
     
     
    Item 10.
    Certification
      
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.
     
     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
     
     MANAGED ACCOUNT ADVISORS LLC 
        
    Date: January 26, 2022
    By:
    /s/  Carlos A. Torres  
        Carlos A. Torres  
        Title:  Authorized Signatory  
        
     
    Footnotes:
    Attention:
    Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)
     
     

    Get the next $OSUR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OSUR

    DatePrice TargetRatingAnalyst
    1/3/2023$5.00In-line
    Evercore ISI
    2/24/2022$15.00 → $12.00Buy
    Citigroup
    9/22/2021Outperform → Market Perform
    Raymond James
    8/4/2021$11.00 → $12.50Outperform
    Raymond James
    6/28/2021$12.00 → $11.00Outperform
    Raymond James
    More analyst ratings

    $OSUR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by OraSure Technologies Inc.

      SC 13G/A - ORASURE TECHNOLOGIES INC (0001116463) (Subject)

      11/12/24 4:46:06 PM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by OraSure Technologies Inc.

      SC 13G/A - ORASURE TECHNOLOGIES INC (0001116463) (Subject)

      11/4/24 1:18:55 PM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by OraSure Technologies Inc.

      SC 13G - ORASURE TECHNOLOGIES INC (0001116463) (Subject)

      10/4/24 1:30:36 PM ET
      $OSUR
      Medical/Dental Instruments
      Health Care

    $OSUR
    Financials

    Live finance-specific insights

    See more
    • OraSure Announces First Quarter 2025 Financial Results

      BETHLEHEM, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended March 31, 2025. "Our Q1 results were consistent with our expectations. Our customers continue to demonstrate their preference for our differentiated products in delivering on their important health objectives, even while uncertainty remains elevated related to government funding sources for some segments," said OraSure President and CEO Carrie Eglinton Manner. "We are making good progress in advancing our innovation roadmap, including multiple new prod

      5/7/25 4:05:00 PM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • OraSure to Announce First Quarter 2025 Financial Results and Host Earnings Call on May 7th

      BETHLEHEM, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular earnings conference call covering first quarter 2025 financial results and certain business developments for 5 p.m. ET on May 7, 2025. A webcast of the conference call will be available on the investor relations page of OraSure's website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webcast will be archived on OraSure's website shortly after the call has ended and will be available for approximately one year. For participants interested

      4/23/25 4:05:00 PM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • OraSure Reports Fourth Quarter 2024 Financial Results

      BETHLEHEM, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended December 31, 2024. "Our Q4 revenue was consistent with our expectations, including 10% growth in our core revenue. We continue to see signs of gradual recovery in our key end markets, and we are diversifying our business by expanding our product portfolio and adding new customers, offset by elevated uncertainty for some of our existing customers related to government funding sources," said OraSure President and CEO Carrie Eglinton Manner. "We made tre

      2/25/25 4:05:00 PM ET
      $OSUR
      Medical/Dental Instruments
      Health Care

    $OSUR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $OSUR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Evercore ISI resumed coverage on OraSure with a new price target

      Evercore ISI resumed coverage of OraSure with a rating of In-line and set a new price target of $5.00

      1/3/23 8:07:55 AM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • Citigroup reiterated coverage on OraSure Technologies with a new price target

      Citigroup reiterated coverage of OraSure Technologies with a rating of Buy and set a new price target of $12.00 from $15.00 previously

      2/24/22 8:34:18 AM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • OraSure Technologies downgraded by Raymond James

      Raymond James downgraded OraSure Technologies from Outperform to Market Perform

      9/22/21 5:02:16 AM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • Director Gagliano Nancy J bought $39,270 worth of shares (12,750 units at $3.08), increasing direct ownership by 16% to 91,524 units (SEC Form 4)

      4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

      3/3/25 9:08:13 AM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • President & CEO Eglinton Manner Carrie bought $100,027 worth of shares (28,670 units at $3.49), increasing direct ownership by 2% to 1,288,334 units (SEC Form 4)

      4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

      3/3/25 9:07:25 AM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • President & CEO Eglinton Manner Carrie bought $247,378 worth of shares (78,625 units at $3.15), increasing direct ownership by 7% to 1,259,664 units (SEC Form 4)

      4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

      2/27/25 9:14:53 PM ET
      $OSUR
      Medical/Dental Instruments
      Health Care

    $OSUR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Targeted Genomics Announces Commercial Collaboration with OraSure Technologies for Direct to Consumer (DTC) Celiac Genetic Testing

      IRVINE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Targeted Genomics LLC, developer of GlutenID, the first and only U.S. Food and Drug Administration (FDA) cleared direct-to-consumer (DTC) test for celiac disease genetics, today announced a commercial collaboration with OraSure Technologies, Inc. (NASDAQ:OSUR) manufacturer of ORAcollect®·Dx, the only FDA cleared saliva collection device for general over-the-counter (OTC) use. The collaboration expands consumer access to at-home celiac genetic testing.  Celiac disease, the most common intestinal autoimmune disease worldwide, is triggered by dietary gluten in people who carry the DQ2 and/or DQ8 celiac risk genes. Individuals who test negative

      5/14/25 8:00:00 AM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • OraSure Announces First Quarter 2025 Financial Results

      BETHLEHEM, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended March 31, 2025. "Our Q1 results were consistent with our expectations. Our customers continue to demonstrate their preference for our differentiated products in delivering on their important health objectives, even while uncertainty remains elevated related to government funding sources for some segments," said OraSure President and CEO Carrie Eglinton Manner. "We are making good progress in advancing our innovation roadmap, including multiple new prod

      5/7/25 4:05:00 PM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • OraSure to Announce First Quarter 2025 Financial Results and Host Earnings Call on May 7th

      BETHLEHEM, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular earnings conference call covering first quarter 2025 financial results and certain business developments for 5 p.m. ET on May 7, 2025. A webcast of the conference call will be available on the investor relations page of OraSure's website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webcast will be archived on OraSure's website shortly after the call has ended and will be available for approximately one year. For participants interested

      4/23/25 4:05:00 PM ET
      $OSUR
      Medical/Dental Instruments
      Health Care

    $OSUR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President & CEO Eglinton Manner Carrie covered exercise/tax liability with 193,249 shares and was granted 335,710 shares, increasing direct ownership by 8% to 1,830,827 units (SEC Form 4)

      4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

      6/5/25 7:16:13 PM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • Director Kenny John P. was granted 71,017 shares, increasing direct ownership by 102% to 140,547 units (SEC Form 4)

      4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

      5/15/25 4:46:39 PM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • Director Gagliano Nancy J covered exercise/tax liability with 4,387 shares and was granted 71,017 shares, increasing direct ownership by 73% to 158,154 units (SEC Form 4)

      4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

      5/15/25 4:46:26 PM ET
      $OSUR
      Medical/Dental Instruments
      Health Care

    $OSUR
    Leadership Updates

    Live Leadership Updates

    See more

    $OSUR
    SEC Filings

    See more
    • KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, June 7, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from the S

      6/7/24 6:09:00 PM ET
      $ADTN
      $ALTR
      $ATNI
      $BMRN
      Telecommunications Equipment
      Utilities
      Computer Software: Prepackaged Software
      Technology
    • NOWDiagnostics Welcomes Dr. Stephen S. Tang as Chairman of the Board

      Former Head of OraSure Technologies Joins at Key Stage Leading up to Company's Product Launch NOWDiagnostics (NOWDx), a developer of over-the-counter (OTC) and point-of-care (POC) diagnostics tests and first-in-class technology and platforms, today announced the appointment of Dr. Stephen S. Tang, Ph.D., MBA, as the chairman of the company's board of directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321747977/en/NOWDiagnostics (NOWDx) Welcomes Dr. Stephen S. Tang as Chairman of the Board (Photo: Business Wire) Dr. Tang is a longtime veteran of the medical diagnostic industry. He led OraSure Technologies, Inc. (NASDA

      3/21/24 8:31:00 AM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • OraSure Technologies Announces the Retirement of Jack E. Jerrett and Appointment of Agnieszka M. Gallagher as General Counsel, Chief Compliance Officer and Secretary

      BETHLEHEM, Pa., Nov. 09, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that after almost 21 years of service to the Company, Jack E. Jerrett is retiring as the Company's Senior Vice President, General Counsel, Chief Compliance Officer and Secretary, effective as of December 31, 2021. Agnieszka M. Gallagher, who most recently served as the Chief Ethics and Compliance Officer at Alnylam Pharmaceuticals has been hired by the Company to fill Jack's roles as the new General Counsel, Chief Compliance Officer and Secretary. "Jack has been a stalwart and extremely

      11/9/21 7:05:00 AM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by OraSure Technologies Inc.

      EFFECT - ORASURE TECHNOLOGIES INC (0001116463) (Filer)

      5/30/25 12:15:20 AM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 filed by OraSure Technologies Inc.

      S-8 - ORASURE TECHNOLOGIES INC (0001116463) (Filer)

      5/20/25 5:26:03 PM ET
      $OSUR
      Medical/Dental Instruments
      Health Care
    • SEC Form S-3 filed by OraSure Technologies Inc.

      S-3 - ORASURE TECHNOLOGIES INC (0001116463) (Filer)

      5/20/25 5:13:17 PM ET
      $OSUR
      Medical/Dental Instruments
      Health Care